www.salvohealth.com Open in urlscan Pro
52.17.119.105  Public Scan

Form analysis
1 forms found in the DOM

Name: email-form — GET

<form id="email-form" name="email-form" data-name="Email Form" method="get" class="footer_field" data-wf-page-id="655bd4faf05ea18a424ffa6e" data-wf-element-id="1b1ae172-a0d3-e8bf-a7c7-af9e017494d3" aria-label="Email Form"><input
    class="footer_input w-input" maxlength="256" name="email-2" data-name="Email 2" placeholder="Enter your email" type="email" id="email-2" required="">
  <div class="footer_submit-block"><input type="submit" data-wait="" class="footer_submit w-button" value=""></div>
</form>

Text Content

Salvo Health raises $5M to expand GI Provider Enablement for Wraparound Care
Payers


Providers


The Science

About Us

Blog

Get In Touch






Press
—


SALVO HEALTH RAISES $5M TO EXPAND GI PROVIDER ENABLEMENT FOR WRAPAROUND CARE



Published:

February 28, 2024

Written by:






Medically Reviewed by:






Published:

February 29, 2024

In The News
In The News

New York, February 29th - Salvo Health today announced the closing of a $5
million Seed Prime round led by City Light Capital and Human Ventures to expand
deployment of its wraparound GI care at providers including gastroenterology
private practices, health systems, and ACOs.


‍

The financing included investment pro rata from all three of Salvo’s original
Seed investors: Threshold Ventures, Torch Capital, and Felicis Ventures, as well
as angel investors such as Anmol Madan, founder of Ginger Health and former
Chief Data Scientist at Teladoc. 




Salvo also announced that Rachel Parlier of City Light and Emily Melton of
Threshold will join the Board of Directors, alongside Jeffrey Glueck, the
Founder & CEO of Salvo. Parlier helped lead City Light investments in innovators
such as Bicycle Health and Spark Pediatrics. Melton, managing director and
co-founder of Threshold, is a recent past Chair of the Board of the National
Venture Capital Association (NVCA) and has led investments in Livongo,
Brightline, Imagen, Tia, and Viz.ai. Glueck, who launched Salvo in 2021,
formerly served as CEO of Foursquare and as product leader and Chief Marketing
Officer at Travelocity.


‍

"I am delighted to lead this investment in Salvo Health and their innovative
wraparound care for GI and metabolic chronic conditions," said Rachel Parlier of
City Light Capital. "As an early-stage impact investor, we look for companies
with the potential to not just transform industries, but also to improve lives.
Salvo is enabling GI practices and health systems to fill in the gaps for
underserved patient populations, especially for high-touch follow-on care
between appointments and post-procedures."

‍

“An estimated 70 million Americans are suffering from chronic gastrointestinal
conditions that can cause serious disruptions to daily life,” noted Heather
Hartnett, General Partner at Human Ventures. “The growing need for GI care has
surpassed the supply of specialists, and Salvo Health plays an important role in
filling this gap. We’re thrilled to be backing such an experienced, data-driven,
and product-focused team led by Jeff, that is poised to scale significant
clinical outcomes.”

‍

Salvo Health focuses on enabling local providers across the country to provide
“wraparound care” for chronic GI and metabolic liver conditions in a hybrid
approach. Patients remain under the care of their trusted local physician,
adding the best of Salvo telehealth and app-based daily support for follow-on
care. Salvo helps solve staff shortages and clinician burnout by enabling
insurance-covered, evidence-based, interdisciplinary care including Salvo’s
teams of licensed nurses, registered dietitians, and behavioral health
specialists. 

‍

Salvo enables providers to bill RPM and CCM codes for both Medicare and
commercial patients where such codes are broadly covered, thereby improving
patient outcomes and generating new ancillary service revenue for practices.
This positions large practices and systems on the path to value-based care
arrangements, including shared savings and quality incentives. The model also
frees busy providers to see more acute cases and more new patients by enabling
patients to access daily support from their team at Salvo.

‍

Unlike some startups in the GI space that focus on disintermediating or
bypassing local physicians while serving national payers or as an employer
benefit, Salvo’s philosophy is to make the local physician the hub of an
interdisciplinary, personalized care plan for each patient.  

‍

Salvo has won deals with GI practices from Brooklyn to Pennsylvania to Virginia,
and with a large health system in Baton Rouge, LA. This financing will fund
staff-up to execute on these enterprise deployments, and expand sales and
marketing to new customers.

‍

The success of this hybrid “continuous care” approach was highlighted in
research published at the annual meeting of the American College of
Gastroenterology (ACG) in November 2023. Salvo Clinical Advisory Board eminent
physician-researchers including Dr. Mark Pimentel of Cedars-Sinai, Dr. Megan
Oser of UCLA Medical, and Dr. Peter Green of Columbia were co-authors on the
research.

‍

84% of patients described Salvo as better than previous healthcare experiences.
76% reported symptom improvement after only four or more weeks in Salvo care,
notable since patients had averaged over three years of chronic symptoms before
intake. Patients showed high engagement, averaging five questions a week handled
by Salvo care teams, and opening the Salvo app an average of nine times per
week. The median time in care was five months to complete the program. 

‍

In a separate two-arm study, this type of continuous care showed high potential
to deliver better care at lower cost. The treatment arm showed a 79% reduction
in GI-related ER and urgent care utilization, compared to a control group. This
type of proactive care heads off expensive, reactive care. According to a
leading actuary’s study of Total Medical Expense (TME) on over 9 million covered
lives, Salvo has the potential to save payers $3 for every $1 spent on Salvo
care. These savings were projected inside of a one-year measurement window, and
applied also for ACO’s and other population health providers.

‍

Most recently, Salvo announced expansion into wraparound care for MASH and
MASLD, based on requests from its GI and hepatology practices who are
responsible for diagnosis of this liver condition. Metabolic
dysfunction-associated steatotic liver disease (MASLD) is one of the most common
liver conditions worldwide, and the numbers continue to grow. Formerly named
Non-Alcoholic Fatty Liver Disease (or NAFLD), MASLD is estimated to affect
nearly 30% of the U.S. population, rising in parallel to metabolic diseases such
as obesity and diabetes. GI practices and departments generally lack enough
clinical staff trained in behavioral health and nutrition, consumer-friendly
technology and rich medical content, or the analytics and machine learning
expertise to optimally guide patients through a structured weight loss program.
Due to increased use of GLP-1 agonists in treating MASLD, Salvo physician
partners seek to offer their patients medically-supervised, comprehensive
programs to complement these medications, including guidance on resistance
training to maintain muscle mass, cognitive behavioral skills, help building new
nutrition habits, and ensuring adequate micronutrient intake. Salvo's program
has been designed to address these specific needs.

‍

Salvo Health as a technology company has invested deeply in addressing the
shortage of licensed care providers by using software and automation so that
each care team member can support more patients effectively. For Salvo patients
today, two thirds of care minutes each month are delivered by software and
app-based content, while one third of minutes provided by licensed personnel,
letting care teams focus on the highest leverage uses of their time. This
combination keeps a “human touch” and builds a therapeutic alliance with each
patient, and the average response time to patients of under two hours improves
access, in an affordable and scalable way.

 

For practices and health systems that want to speak to our team about how they
can integrate Salvo RPM into their workflow and EHR quickly and efficiently,
contact Amanda Sussex at amanda@salvohealth.com.

‍

ABOUT CITY LIGHT AND HUMAN VENTURES

City Light is a Venture Capital firm that invests early in impactful companies.
The firm partners with experienced teams building category-defining solutions in
the areas of healthcare, education, and climate  — where more revenue equals
better lives at scale, every time. As one of the earliest and most successful
impact investing firms, City Light has a track record of identifying and scaling
impact in ways that build better companies.  Key portfolio investments include
2U (Nasdaq: TWOU), ShotSpotter (Nasdaq: SSTI), Trilogy (Acquired by TWOU),
Ginger (now Headspace Health), and OhmConnect.

‍Human Ventures is one of New York City's premier early-stage venture firms and
startup studios. Human partners with founders from the earliest stages of
building and invests in category-defining companies in the areas of digital
health, future of work, the attention economy and hospitality. Human is deeply
embedded into the fabric of NYC's business community and backs founders who
embody the diversity, resilience, and ambition of NYC. The firm has invested in
and co-built more than 60 companies. Key portfolio investments include
Current.com, Tia Health, Headspace Health, TheSkimm, and Paloma Health.




SHARE THIS ARTICLE






WRITTEN BY:






View Profile


REFERENCES:




RECOMMENDED STORIES


Insights


6 WAYS TO SUPPORT YOUR PATIENTS DURING THE HOLIDAYS & BEYOND

By emphasizing active listening, targeted feedback, patient involvement in
decision-making, flexible options, and encouragement of mindfulness and
movement, you can provide practical strategies to help your patients navigate
holiday challenges while maintaining a focus on long-term health objectives.


Featured


REVOLUTIONIZING THE TREATMENT OF FATTY LIVER DISEASE: INTRODUCING SALVO’S RPM
FOR MASH & MASLD.

Announcing a groundbreaking addition to Salvo Health’s healthcare services that
will transform the treatment of metabolic liver disease through cutting-edge
technology and personalized care.


Press


DIGITAL-FIRST CARE DRIVES STRONG OUTCOMES FOR IBS IN NEW RESEARCH AT THE ACG

Salvo Health and its clinical advisors unveil research at the ACG Annual Meeting
showing dramatic improvement in patients from a continuous-care,
multidisciplinary telehealth approach


Featured


SALVO HEALTH REDUCES ER VISITS, CREATING PATH TO 3:1 ROI

Working with a top actuarial firm, Salvo Health used claims data from over nine
million patients to analyze costs and potential savings for our care model.


Featured


NEW STUDY SHOWS 79% REDUCTION IN GI-RELATED EMERGENCY ROOM VISITS FOR SALVO
HEALTH PATIENTS

Supporting that a continuous, multidisciplinary care model, not only improves
outcomes, but also drives costs down for both patients and the system at large.


Press


SALVO HEALTH PRESENTS LOW FODMAP STUDY AT THE INSTITUTE FOR FUNCTIONAL
MEDICINE'S AIC 2023

AIC 2023: Advancements in Clinical Research and Innovative Practices in
Functional Medicine explores the latest advances in functional medicine research
and offers actionable, clinically relevant insights for creating healthier
outcomes with patients.








GUT THE FACTS — SUBSCRIBE TO THE SALVE

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Careers
Support
Instagram
TikTok
Twitter
LinkedIn
Facebook
Terms of Service
Privacy Policy
© 2024 Salvo Health

335 Madison Ave., New York, NY 10017